Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary moveme...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandopadhyay, Ritam, Mishra, Nainshi, Rana, Ruhi, Kaur, Gagandeep, Ghoneim, Mohammed M., Alshehri, Sultan, Mustafa, Gulam, Ahmad, Javed, Alhakamy, Nabil. A., Mishra, Awanish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/
https://www.ncbi.nlm.nih.gov/pubmed/35462934
http://dx.doi.org/10.3389/fphar.2022.805388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/
https://www.ncbi.nlm.nih.gov/pubmed/35462934
http://dx.doi.org/10.3389/fphar.2022.805388

Ejemplares similares